期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 109, 期 5, 页码 641-649出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI200214380
关键词
-
资金
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI049990, R01AI047133, Z01AI005033] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037513] Funding Source: NIH RePORTER
- NIAID NIH HHS [AI-49990, AI-47133] Funding Source: Medline
- NINDS NIH HHS [R01 NS037513, NS-37513] Funding Source: Medline
Glatiramer acetate (GA; Copaxone) is a random copolymer of glutamic acid, lysine, alanine, and tyrosine that is used therapeutically in patients with multiple sclerosis (MS). To investigate the mechanism of the drug's immunomodulatory effect, we used immunophenotypic approaches to characterize the precise nature of GA-induced T cell responses. We demonstrate here that healthy individuals and untreated MS patients exhibit prominent T cell proliferative responses to GA. However, these responses are different in distinct subsets of T cells. Whereas GA-induced CD4(+) T cell responses are comparable in healthy individuals and MS patients, CD8(+) T cell responses are significantly lower in untreated MS patients. Treatment with GA results in upregulation of these CD8(+) responses with restoration to levels observed in healthy individuals. Both CD4(+) and CD8(+) GA-specific responses are HLA-restricted. GA therapy also induces a change in the cytokine profile of GA-specific CD4(+) and CD8(+) T cells. This study provides the first direct immunophenotypic evidence, to our knowledge, of GA-specific CD8(+) T cell responses and their upregulation during the course of therapy, which may suggest a role for these responses in the immunomodulatory effects of the drug.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据